OncoMatch/Clinical Trials/NCT06752239
Prophylactic Radiotherapy Optimization for Enhanced Thyroid Function Protection in NPC
Is NCT06752239 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies non-drug interventions for nasopharyngeal carcinoma.
This study is a multicenter, non-inferiority, open-label, randomized controlled Phase III clinical trial. It aims to compare the efficacy of modified delineation radiotherapy (experimental group) versus standard delineation radiotherapy (control group) in the prophylactic irradiation of neck lymphatic drainage areas III/IVa in nasopharyngeal carcinoma. The study evaluates the incidence of primary hypothyroidism, quality of life, and adverse events between the two groups.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage I, II, III, IVA
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: radiotherapy
Exception: excluding radiotherapy outside the planned target area for conditions such as melanoma
History of radiotherapy (excluding radiotherapy outside the planned target area for conditions such as melanoma)
Cannot have received: antitumor therapy
Treatment-naïve patients who have not received any prior antitumor therapy
Lab requirements
Blood counts
wbc ≥ 4.0 × 10⁹/l, anc ≥ 1.5 × 10⁹/l, plt ≥ 100 × 10⁹/l, hgb ≥ 90 g/l (no transfusion, blood products, or hematopoietic growth factors used within the past 7 days)
Kidney function
bun and creatinine ≤ 1.5 × uln or creatinine clearance rate ≥ 60 ml/min (calculated using the cockcroft-gault formula)
Liver function
alt and ast < 1.5 × uln, alp < 2.5 × uln, total bilirubin < uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify